Vitamin D supplementation for the treatment of Behcet's disease

A randomized, double-blind controlled study of the efficacy of vitamin D supplementation compared with placebo on treatment of Behcet's disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201212216975N4

Enrollment

Registered

2013-03-20

Start date

2013-04-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet's disease. Behçet disease

Interventions

Intervention 1: The treatment group will receive vitamin D soft gel (D-VITIN, Zahravi) containing 50000 units of cholecalciferol [(3ß,5Z,7E)-9,10-secocholesta- 5,7,10(19)-trien-3-ol] one soft gel oral

Treatment - Drugs

The treatment group will receive vitamin D soft gel (D-VITIN, Zahravi) containing 50000 units of cholecalciferol [(3ß,5Z,7E)-9,10-secocholesta- 5,7,10(19)-trien-3-ol] one soft gel orally after meal e

The control group will receive one soft gel containing placebo orally after meal every 2 weeks for 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Having active Behcet’s disease: Iranian Behcet's Disease Dynamic Activity Measure (IBDDAM) more than 2.5 Exclusion criteria: 1. Consumption of vitamin D supplements in the past 6 months 2. Pregnancy 3. Malabsorption 4. Renal failure 5. Hepatic failure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Behcet's disease activity. Timepoint: Before intervention, 3 and 6 months after intervention. Method of measurement: Iranian Behcet’s Disease Dynamic Activity Measure questionnaire.	—

Secondary

Measure	Time frame
Complications of vitamin D supplementation. Timepoint: 3 and 6 months after the intervention. Method of measurement: History and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrzad Hajiallilo

Tabriz University of Medical Sciences

hajialilo@gmail.com+98 41 1337 3966

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026